Kaposiform hemangioendothelioma (KHE) is an aggressive disease with high morbidity and mortality. The aim of this study was to retrospectively evaluate the efficacy and safety of sirolimus for the treatment of progressive KHE. A multicenter, retrospective cohort study was conducted in patients with progressive KHE treated with sirolimus. A total of 52 patients were analyzed. Thirty-seven (71%) patients exhibited Kasabach-Merritt phenomenon (KMP) and were significantly younger than the patients without KMP [95% confidence interval (CI), 14.39-41.61; p < 0.001]. Patients without KMP were all treated with sirolimus alone, whereas 21 KMP patients with severe symptoms received short-term combination therapy with prednisolone. Overall, 96% and 98% of patients showed improved relief of notable symptoms and/or improved complications at 6 and 12 months after treatment, respectively. After sirolimus treatment, significant decreases in mean severity scores occurred at 6 months (95% CI, 2.23-2.54, p < 0.001) and 12 months (95% CI, 1.53-1.90, p < 0.001). Compared to KMP patients, patients without KMP showed a response that was similar to but less pronounced during the 12 months of treatment (95% CI, 40.87-53.80; p < 0.001). For subgroup analysis of KMP patients, there were no significant differences in tumor shrinkage between those treated with combination therapy and those receiving sirolimus alone (95% CI, 18.11-25.02; p > 0.05). No patients permanently discontinued treatment due to toxicity-related events, and no drug-related deaths occurred. Sirolimus was effective and safe for the treatment of progressive KHE. Sirolimus may be considered as a first-line therapy or as part of a multidisciplinary approach for the treatment of KHE.
Kaposiform hemangioendothelioma (KHE) is a rare vascular neoplasm that occurs predominantly in infancy or early childhood. KHE has a nearly equal sex ratio. The annual incidence of KHE has been estimated at 0.071 per 100,000 children. 1 KHE presents with intermediate-malignant and locally aggressive characteristics but without distant metastases. >70% of KHE patients develop a life-threatening thrombocytopenia and consumptive coagulopathy, known as Kasabach-Merritt phenomenon (KMP). Additionally, KHE may be complicated by severe anemia due to blood sequestration and intralesional hemorrhaging. KHE has notably high morbidity and mortality rates, resulting predominantly from rapid tumor growth and infiltration, compression or destruction of vital structures and hemodynamic instability. [2] [3] [4] Although complete surgical resection has been acknowledged as the curative gold standard for KHE, total resection is often not a viable option due to a high risk of bleeding, the extent of the tumor and/or the anatomic site of the lesion. 5 Consensus treatment guidelines from a multidisciplinary expert panel were published in 2013. Medical treatments with corticosteroids and/or vincristine have been recommended for the management of KHE. 6, 7 However, first-line treatment with corticosteroids is successful in only 10-27% of all cases, and treatment with vincristine is successful in 60-70% of patients. 8, 9 Moreover, vincristine monotherapy has not been confirmed to provide significant benefits in critically ill patients. [10] [11] [12] [13] Currently, the optimal therapeutic agent or combination of agents remains undetermined. Standard protocols are inadequate because responses to therapy are variable and unpredictable. In many cases, multiple agents are given in sequence or in combination. [10] [11] [12] 14 Sirolimus (also known as rapamycin) is an inhibitor of the mammalian target of rapamycin (mTOR). In recent studies, sirolimus was shown to be effective in patients with complex vascular anomalies, including KHE. The authors described a reduction in KHE size, an eventual normalization of platelet counts in KMP patients, and in some cases, improvements in musculoskeletal pain and function. [15] [16] [17] [18] [19] [20] [21] [22] [23] However, the relative benefits and risks of sirolimus in KHE patients remain unclear.
The goal of the present study was to assess the efficacy, safety and tolerance of sirolimus in patients with progressive KHE.
Methods
This study was a retrospective multicenter cohort study conducted in China from January 2011 to October 2015. Approval was obtained by the West China Hospital of Sichuan University Institutional Review Board, the study site of the principal investigator, and by the local institution review boards at each participating site. All procedures were conducted according to the Declaration of Helsinki. Parents gave written, informed consent for the use of drugs in the treatment of KHE. Written, informed consent for the use of patients' information and images was also obtained. The study included patients with clinical features and histological findings consistent with progressive, nonresectable KHE who were treated with sirolimus. Progressive KHE was characterized as a symptomatic tumor requiring treatment, which was defined by dramatic tumor growth, functional impairment and/or the presence of KMP. KHE was classified as mixed or deep according to the radiographic and/or histological findings. Mixed KHE was defined as a cutaneous lesion with deep infiltration into subcutaneous tissue, fascia, muscle, bone, intrathoracic or retroperitoneal sites. Deep KHE was defined as a noncutaneous lesion located in the mediastinum, retroperitoneum, internal organs or bones and joints. Such lesions may infiltrate into surrounding structures. KMP was defined as a platelet count of <100 3 10 9 /L. 1 Clinical information, including demographics, clinical presentation, physical findings, laboratory results and treatment, were assessed at baseline, at the initiation of each treatment regimen, at 1, 2, 3, 6, 9 and 12 months after sirolimus treatment, at each scheduled visit and at the last available visit.
A successful treatment response was defined as an improvement in the patient's symptoms and/or complications, the restoration of hematologic parameters and a reduction in KHE volume. Severity was scored by investigators on a scale from 1 to 4 as follows: 1, asymptomatic or mild symptoms; 2, moderate symptoms, limiting age-appropriate instrumental activities of daily living (ADL); 3, severe symptoms or medically significant but not immediately life-threatening, limiting self-care ADL and 4, life-threatening consequence, with urgent intervention indicated. For each patient, a notable improvement in symptoms and/or complications was defined as a decrease in the severity score of 1. Volumetric magnetic resonance imaging (MRI) analyses were performed at baseline and 6 and 12 months after treatment and were independently assessed by two radiologists. Changes in KHE size were classified as further growth (increase of 10%), no change (<10% increase and <10% decrease), partial involution (decrease of 10% and <75%), nearly complete involution (decrease of 75% and <100%) or complete involution (100%).
What's new? Kaposiform hemangioendothelioma (KHE) is an aggressive disease with high morbidity and mortality. Responses to standard therapies have been variable and unpredictable. In this study, the authors found that the drug sirolimus (rapamycin) provides a safe and effective treatment option for patients with progressive KHE. They caution, however, that the regimen should be tailored to individual patients. In cases complicated by Kasabach-Merritt phenomenon (KMP), a life-threatening coagulopathy, the short-term addition of prednisolone is also recommended.
Safety was monitored at the scheduled visits by physical examination and routine laboratory studies. All adverse events were collected and graded according to Common Terminology Criteria for Adverse Events, version 4.0 (CTCAE v4.0). The causality of the adverse event was determined by the multidisciplinary staff and was classified as definitively not related, probably not related, possibly related, probably related or definitively related. Any dose reductions, interruptions or cessations enacted at the discretion of the investigators were recorded.
Statistical Analysis
Data are presented as the means with ranges for continuous variables and as frequencies with percentages for qualitative variables. Statistical analyses were conducted using SPSS 22 
Results

Demographic and Clinical Characteristics
Fifty-two patients diagnosed with KHE were included in the study. None of the patients had been reported in our previous studies. 18, 19 Their baseline characteristics are summarized in Table 1 and Supporting Information Tables 1 and 2 . The mean age at sirolimus treatment initiation was 10.6 months (range, 0.5 to 98.0). Included were 25 males and 27 females, with a male-to-female ratio of 1:1.08. The tumors were predominantly located in the extremities, where 50% of all the KHEs occurred. Eight (15%) patients had KHE lesions that extended into more than one anatomic region. No patients had multifocal lesions. The mixed subtype accounted for 87% of the KHEs in the cohort. Ten (19%) patients had tumorinduced bone and/or joint destruction. Overall, 21 (40%) patients had been treated previously with at least one medical therapy for KHE. All these treatment regimens produced insufficient responses (Table 1) .
Thirty-seven (71%) patients sustained KMP. They were significantly younger than the patients without KMP [95% confidence interval (CI), 14.39-41.61; p < 0.001] ( Table 1) . The mean platelet count was 18 3 10 9 /L (range, 3 to 63 3 10 9 /L). Acquired hypofibrinogenemia (a fibrinogen level <1.0 g/L) was observed in 27 patients. Seven patients had severe anemia (hemoglobin concentration <80 g/L) (Supporting Information Table 3 ).
Treatment
Sirolimus was initiated at a dosage of 0.8 mg/m 2 administered twice daily. Subsequently, the sirolimus dosage was adjusted monthly to achieve trough levels between 10 and 15 ng/mL. Thirty-one patients were treated with sirolimus alone. Six KMP patients experienced progressive enlargement of their tumor lesions even after the initiation of sirolimus monotherapy (Supporting Information Fig. 1 ). Due to the ongoing thrombocytopenia and coagulopathy, as well as progressive compression symptoms, a short-term combination treatment with prednisolone (2 mg/kg/d) was administered. The remaining 15 KMP patients received an initial combination therapy (sirolimus and prednisolone). Fresh frozen plasma and/or cryoprecipitate were given to patients to treat consumption coagulopathy and hypofibrinogenemia in the following circumstances: i) active bleeding; ii) platelet count <10 3 10 9 /L and/or iii) fibrinogen <0.5 g/L. In all patients, prednisolone was subsequently tapered and eventually discontinued and was followed by single-agent sirolimus treatment. The average duration of prednisolone therapy was 7.2 weeks (range, 6.0 to 9.0 weeks). In one patient (Patient #13) without KMP, treatment was discontinued at month 7 due to a lack of efficacy. At the last followup, 27 patients had been successfully tapered off sirolimus. The mean duration of sirolimus treatment in these patients was 20.5 months (range, 13 to 26 months). None of the patients had complete tumor resection during the follow-up period.
Efficacy
Symptoms and complications. Early therapeutic effects, including changes in lesion color and softening of the lesions, were observed in the mixed-type KHEs (Fig. 1) . The KHEs continued to regress after the initial response with associated concurrent symptom relief. The severity scores are shown in Figure 2 and Supporting Information Table 4 . Sirolimus treatment was associated with dramatic decreases in mean severity scores after 6 (95% CI, 2.23-2.54, p < 0.001) and 12 (95% CI, 1.53-1.90, p < 0.001) months. Overall, 96% (50/52) and 98% (50/51) of patients experienced notable improvement in symptoms and/or complications at 6 and 12 months after treatment, respectively (Supporting Information Table  5 ). None of the patients died from KHE or KHE-related complications during the follow-up period.
Hematologic parameters. All KMP patients experienced improvement in their hematologic parameters. As shown in Supporting Information Table 6 , the mean stabilization period for platelet counts (>100 3 10 9 /L) was 14 days (range, 6 to 26 days). In patients with hypofibrinogenemia, gradual increases in fibrinogen levels were observed after oral sirolimus was initiated. The mean stabilization period for fibrinogen levels (>1.0 g/L) was 5.0 weeks (range, 3.5 to 6.5 weeks). Two patients with prior KMP relapsed during the sirolimus monotherapy. Additional courses of prednisolone were administered with subsequent normalization of the platelet counts.
Imaging findings. The reduction in KHE size was determined by MRI (Fig. 3) . Overall, a 75% reduction in tumor size was achieved in 46% of patients after 6 months of treatment. From 6 to 12 months, the KHEs continued to regress but less markedly compared to the changes observed during the first 6 months of treatment (95% CI, 22.19-33.02; p < 0.001). After 12 months of therapy, a 75% reduction in tumor size was achieved in 71% of patients (Supporting Information Table 5 ). Patients without KMP showed a response that was similar to but less pronounced than that in patients with KMP (95% CI, 40.87-53.80; p < 0.001) (Fig. 4a and Supporting Information Table 7 ). In the KMP subgroup, no significant differences in tumor shrinkage were noted between the patients treated with combination therapy and those receiving sirolimus alone (95% CI, 18.11-25.02; p > 0.05) (Fig. 4b) . None of the patients showed complete lesion eradication at their last follow-up.
Safety and Tolerance
During the mean treatment period of 18.0 months (range, 7.0 to 27.0 months), 112 events graded as 1 and higher were identified by the investigators as at least possibly treatment related. The most common events were gastrointestinal disorders.
Other common events that occurred in >10% of patients primarily involved the five categories of blood and lymphatic system disorders, metabolic disorders or other abnormal laboratory results, skin disorders and general disorders. Grade 3 and 4 events occurred in 13 and 2 patients, respectively, and these grades were the maximum observed (Table 2) . Sirolimus, whether alone or in combination with prednisolone, was generally well tolerated in the children. Six patients required a total of seven dose reductions due to toxicity-related adverse events: four in patients receiving monotherapy and three in patients receiving combination therapy. Three patients required a total of three rest periods of 2-3 weeks prior to resuming treatment: two in patients receiving monotherapy and one in patients receiving combination therapy. No appreciable differences were noted between the patients treated with combination therapy and those receiving sirolimus alone with regard to dose reductions and/or treatment discontinuation (p > 0.05). No toxicity-related permanent treatment discontinuation or drug-related deaths occurred during the follow-up period.
Discussion
A few recent studies have demonstrated that sirolimus had a positive effect on reducing KHE progression in patients with or without KMP. [15] [16] [17] [18] [19] [20] [21] [22] [23] However, these findings were based on relatively small sample sizes. 24 To confirm the effects of sirolimus in the treatment of KHE, more extensive clinical studies are required. In the present study, we provide further clinical evidence of the efficacy, safety and tolerability of sirolimus in patients with progressive KHE, whether used alone or in combination with prednisolone. To the best of our knowledge, this is the largest reported study of KHE patients treated with medical therapy. Treatment is problematic for KHE patients whose tumors are unresponsive to conventional therapies. In the present study, oral sirolimus was effective in controlling the growth of KHEs and providing a rapid improvement in hematopoietic parameters. Remarkably, patients who were previously resistant to the prolonged use of conventional drugs showed excellent responses to sirolimus. The size of their tumors reduced, and they experienced notable improvement in their symptoms and complications. Most importantly, the effects of sirolimus were largely constant.
Patients with KHE showed substantial variation in their disease severity and responses to different treatment regimens. Due to the marked heterogeneity of KHE, there were wide variations in the clinical management and treatment protocol employed by the participating centers. Coagulopathy and thrombocytopenia in KHE are typically associated with more aggressive presentations and poorer outcomes. Therefore, the chosen treatment regimen should be based on the individual patient and his or her treatment response. 6, 7, 14, 25 In cases of active bleeding, severe coagulopathy and/or thrombocytopenia, fresh frozen plasma and/ or cryoprecipitate can be used in the management of KMP. Transfusion of packed red blood cells should be given if the patient has symptomatic anemia (hemoglobin concentration <80 g/L). Lesions involving the neck, viscera, retroperitoneum and mediastinum are associated with a particularly high mortality. [26] [27] [28] [29] The clinical management of these high-risk KMP patients is highly challenging. To date, no single treatment regimen has provided consistently reproducible results in terms of decreased tumor size and KMP symptom control. 6, 9, 14 Should deterioration ensue during treatment, a combination therapy or an alternative treatment should be considered. However, when sirolimus is not effective, no clinical data are available to conclusively determine the appropriate second-line management for such refractory. Furthermore, KMP patients with a high probability of long-term sequelae, such as those with functional deformities or severe life-threatening conditions, should be treated aggressively. In our study, the shortterm application of combined sirolimus and prednisolone was effective in managing these cases. Remarkably, dramatic and rapid responses to this combination therapy were reported in patients with severe KMP who had not improved satisfactorily upon initial treatment with sirolimus alone. These findings suggest a potential additive or synergistic effect of sirolimus and prednisolone in the treatment of KMP. Interestingly, in vivo and in vitro studies have demonstrated that sirolimus and corticosteroids exert antiangiogenic effects via distinct mechanisms in infantile hemangioma (IH), although preclinical data on KHE are lacking. [30] [31] [32] [33] Notably, sirolimus has been shown to inhibit lymphangiogenesis. 34, 35 Angiogenesis and lymphangiogenesis are both assumed to be involved in KHE pathogenesis and platelet trapping. 36 Corticosteroids have played a significant role in KHE and IH management over the past few decades. The dosage recommendations for prednisolone in KHE and IH are 2 and 2-3 mg/kg per day, respectively. 7, 37 Generally, prednisolone therapy for vascular tumors in young children has been welltolerated. However, adverse effects, such as temporary growth retardation, hypothalamic-pituitary-adrenal axis suppression and behavioral changes, are commonly reported. 38 Therefore, the duration of the prednisolone combination regimen should also be individualized. Moreover, our data analysis revealed that the mean changes in tumor volume from baseline to 6 and 12 months did not differ significantly between sirolimus monotherapy and the combination treatment in the KMP patients. Thus, additional prednisolone therapy did not appear to accelerate subsequent lesion involution. Considering the undesirable side effects of long-term corticosteroid use in children, prednisolone should be weaned as soon as medically feasible. Should satisfactory clinical responses and hematologic stabilization ensue, prednisolone may be tapered and discontinued within the following 4-6 weeks.
We found that sirolimus treatment promoted more prominent decreases in tumor size during the first 6 months of treatment than in the second 6 months of treatment. Notably, however, no patients sustained complete tumor involution at their last follow-up. In some of our patients, although their associated symptoms and complications improved markedly, their lesions evolved and changed quite slowly, showing only slight or partial decreases in size. Typically, complete KHE involution is rare, notwithstanding prolonged pharmacologic treatment. 39 Residual lesions or dense fibrosis are common, particularly in patients with prominent muscle involvement during KMP. Therefore, unless the sirolimus treatment continues to alleviate symptoms and/or complications (e.g., decreased range of motion), once maximum improvement has been achieved, no further reason exists to continue with sirolimus therapy provided the high-risk symptoms have resolved and the lesions are stable on serial imaging.
Although the rationale and safety of long-term sirolimus use in organ transplant recipients has been confirmed, [40] [41] [42] the safety and tolerance of such use of this agent in young children with KHE have not been well documented. In the present study, we provide further evidence that sirolimus, whether alone or in combination with prednisolone, was well-tolerated in KHE patients whose trough levels were within 10-15 ng/mL. Although adverse events were common, few patients required dose adjustments or temporary treatment discontinuation due to drug toxicity. These findings are consistent with studies in children with plexiform neurofibromas and other vascular anomalies.
22,43 Nonetheless, several rare but potentially serious adverse events have been associated with this class of agents. 35, 42, 44 Additionally, the potential impact of mTOR inhibitors on the physical development of young children raises substantial concerns about these drugs. Growth inhibition has been reported in pediatric kidney-transplant patients receiving sirolimus. 45 Considering that the mean period of the sirolimus adverse-effect profile in the present study was only 18 months, future studies must carefully evaluate the long-term safety of sirolimus in young children.
Some limitations of this study include its retrospective nature and the wide variations in the clinical management and treatment protocol employed by the participating centers. The evaluation of the time-course effects of prednisolone was difficult due to the rarity of KHE and the resultant small cohort size. Moreover, due to the marked heterogeneity of KHE, no validated assessments of KHE disease severity are currently available. However, the dosage and schedules for sirolimus were standardized in all our patients. Regular patient fellow-up is an additional strength of the current study. Our outcome assessments involved standardized image analyses and independent readings. The data from these standardized procedures provide abundant information.
Conclusions
This report is the largest study assessing the efficacy of sirolimus, whether alone or in combination with short-term prednisolone, in patients with progressive KHE. We demonstrated satisfactory efficacy of these drugs with a reasonable safety profile. Additionally, our data emphasize that the KHE treatment regimen should be tailored to individual patients and guided by specific clinical circumstances. Although more extensive prospective data are lacking, our current study suggests that sirolimus may be used as a firstline therapy or as part of a multidisciplinary approach in KHE patients whose tumors warrant treatment. Future prospective, randomized and controlled studies are needed to extend these conclusions toward improved care of patients with progressive KHE.
